A5034784898- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cervical Cancer and HPV Research
- Economic and Financial Impacts of Cancer
- Diversity and Career in Medicine
- Extracellular vesicles in disease
- Inflammatory Biomarkers in Disease Prognosis
- Healthcare Systems and Challenges
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- HER2/EGFR in Cancer Research
- Ultrasound and Hyperthermia Applications
- Monoclonal and Polyclonal Antibodies Research
- Cardiac, Anesthesia and Surgical Outcomes
- Ultrasound Imaging and Elastography
- Pancreatic and Hepatic Oncology Research
- Orthopaedic implants and arthroplasty
- Caveolin-1 and cellular processes
- Nanoparticle-Based Drug Delivery
- Metabolism, Diabetes, and Cancer
- Pelvic and Acetabular Injuries
- Mentoring and Academic Development
- Musculoskeletal synovial abnormalities and treatments
The Ohio State University
2020-2024
OhioHealth
2019-2024
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2022-2024
Ohio Department of Health
2024
The Ohio State University Wexner Medical Center
2020-2023
Health and Human Development (2HD) Research Network
2022
Huntsman Cancer Institute
2020
University of Utah
2020
Riverside Methodist Hospital
2017-2019
Effective second-line treatment options for patients with recurrent ovarian clear cell carcinoma (OCCC) are limited. This case series sought to report tumor characteristics and oncologic outcomes in a small group of treated combination lenvatinib pembrolizumab. A retrospective analysis pembrolizumab at single institution was performed. Patient were collected including demographics germline/somatic testing. Clinical also evaluated reported. Three OCCC included the study. The median age 48...
Ovarian cancer typically presents at an advanced stage and while initial chemotherapy response rates are favorable, a majority of patients experience recurrence with the subsequent development chemoresistance. Recurrent, platinum-resistant disease is associated very poor prognosis as treatment in this setting often limited by systemic toxicity. Antibody-drug conjugates (ADCs) novel therapeutic agents designed to target antigens specific ovarian tumor cells direct delivery cytotoxic combat...
• Leadership training is under-emphasized in traditional medical education. An effective leadership curriculum must be dynamic and requires genuine investment from participants. Through didactic education, self-reflection, real-world perspective we can actively mold future leaders gynecologic oncology.
Background Patients in rural areas have a higher incidence of cervical cancer with increased rates metastatic disease than their urban counterparts. Objective To evaluate whether medical provider density, acting as surrogate for screening availability, is associated the or proportion diagnosed advanced stage disease. Methods Cervical cases by county from 2015 were retrieved SEER database. The numbers primary obstetric-gynecologists (OB-GYN), family practice, and internal medicine providers...
TPS5638 Background: A recent randomized phase III trial demonstrated an improvement in recurrence free and overall survival when heated intraperitoneal chemotherapy (HIPEC) was given at the time of interval cytoreductive surgery (iCRS) for advanced ovarian cancer. While there is rationale HIPEC’s mechanism effect, it remains unclear whether observed benefit because schedule not interrupted perioperatively (typically least 6-8 weeks). We hypothesize that administration same agent similar dose...
To evaluate the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and survival outcomes among patients with recurrent/metastatic cervical cancer treated PD-1/PD-L1 inhibitors.A retrospective analysis of inhibitors from 2016 to 2021 was conducted. Progression free (PFS) overall (OS) were assessed for stratified by NLR (<8 vs ≥ 8) utilizing Kaplan-Meier method. Univariable performed compare baseline characteristics two groups.A total 49 included in analysis. A majority had...
We present a case of 63-year-old female who initially presented with complaints vulvar swelling and was subsequently found to have isolated retroperitoneal lymphadenopathy on imaging. Biopsy performed indicative weakly polarizable material that raised the consideration joint prosthesis wear debris. Due patient's concern for an underlying malignancy gynecologic origin, laparoscopic lymphadenectomy ultimately final pathology consistent reactive changes due debris from bilateral total knee...
INTRODUCTION: Prevention of the primary cesarean section (PCS) is a quality indicator both provider and facility performance. Although nurses spend significant amount time with patients in labor, data lacking regarding influence nursing labor delivery experience on PCS rate. METHODS: A retrospective, institutional review board approved, cohort study 3,275 nulliparous, term singleton fetus vertex presentation was conducted. Labor progression calculated during active phase labor. Nursing...
Background and Objective Ovarian cancer is the deadliest gynecologic malignancy. Although curable in up to 90% of patients diagnosed during early‐stage disease, most are not until late‐stage, at which point, overall 5‐year survival rate less than 25%. This disparity clearly shows that early detection a key factor for improving patient survival. However, there no accurate screening tool available, currently utilized diagnostic modalities lack specificity disease. Transvaginal ultrasound,...
(Abstracted from Gynecol Oncol 2020;158(2):407–414) Individuals diagnosed with endometrial cancer (EC) and presenting early-stage disease have favorable outcomes a high probability of cure compared those advanced disease. Aggressive early interventions including surgery that contribute to good may be less available for various barriers screening health care access, lacking insurance coverage.